Dr. O’Neill has held business development positions ranging from VC incubation through large cap biotech. She is currently Principal at BON Biotech Advsory, LLC, advising and supporting biotech entrepreneurs regarding licensing strategy. She assisted AceLink to successfully in-license a drug development program from large pharma. Previously, she led in-licensing efforts for rare disease assets at BioMarin, and held positions at Elan Pharmaceuticals, Tularik and Guidant. She also has notable out-licensing expertise, having led multiple campaigns with transaction values over $500M.
With an undergraduate degree in biology from MIT, an MBA from the Haas School of Business and a Ph.D. in Molecular and Cell Biology from UC Berkeley, Dr. O’Neill is well positioned for both the business and scientific aspects of her roles. She has excellent alliance management skills, leadership to direct cross functional program evaluation, elegant deal structuring capability, as well as technical depth across therapeutic areas beyond rare diseases including oncology, neurology, metabolic and inflammation.
© Copyright AceLink Therapeutics. All rights reserved